Neuron Specific Enolase (NSE) as Outcome Parameter of Cooling Therapy After Survived Sudden Cardiac Death
NSE as an Outcome Predictor of Therapeutical Hypothermia After Survived Sudden Cardiac Death
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Leipzig, Germany, 04289
- University of Leipzig, Heart Center, Cardiology
-
Leipzig, Germany
- University of Leipzig, Heart Center, Cardiology
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- ROSC after sudden cardiac death (SCA) due to VF/VT or PEA/Asystolia
- GCS 3
Exclusion Criteria:
- Non-cardiac sudden death
- Pregnancy
- Unstable circulation with high-dose inotropics
- Life-expectancy reducing concomitant illness
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Coolgard
invasive cooling
|
invasive cooling via femoral ICY-catheter
Other Names:
|
|
ArcticSun
non-invasive (surface) cooling
|
non-invasive surface cooling by saline-cooled thermo-vest
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
neuron specific enolase (NSE) as a parameter for cerebral damage
Time Frame: 72 hours
|
Blood samples were collected at predefined time-points within 72 hours to measure neuron specific enolase.
|
72 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
neurologic outcome
Time Frame: 6 months
|
At 6 months after cardiac arrest, the cerebral performance category score is assessed to determine neurologic outcome.
|
6 months
|
|
time to overall survival
Time Frame: one year
|
At one year after cardiac arrest, overall survival of the cardiac arrest patients is assessed.
|
one year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Holger Thiele, Associate Professor, study chair
- Study Director: Undine Pittl, MD, Study Sub-Investigator
- Study Director: Alexandra Schratter, MD, Study Sub-Investigator
Publications and helpful links
General Publications
- Sulaj M, Saniova B, Drobna E, Schudichova J. Serum neuron specific enolase and malondialdehyde in patients after out-of-hospital cardiac arrest. Cell Mol Neurobiol. 2009 Sep;29(6-7):807-10. doi: 10.1007/s10571-009-9361-y. Epub 2009 Feb 25.
- Shinozaki K, Oda S, Sadahiro T, Nakamura M, Hirayama Y, Abe R, Tateishi Y, Hattori N, Shimada T, Hirasawa H. S-100B and neuron-specific enolase as predictors of neurological outcome in patients after cardiac arrest and return of spontaneous circulation: a systematic review. Crit Care. 2009;13(4):R121. doi: 10.1186/cc7973. Epub 2009 Jul 22.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- COOL-NSE
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.